VC-backed CoLucid goes public
Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $55 million for its IPO after pricing its 5.5 million shares at $10 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "CLCD." Piper Jaffray & Co. and Stifel are serving as the lead underwriters. CoLucid's backers include TVM Capital Life Science, Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures.
6 May 2015•2 mins read
